查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611226

生物模擬市場規模、佔有率和趨勢分析報告：按產品、按應用、按治療領域、按部署模型、按定價模式、按最終用途、按地區和細分市場預測，2025-2030 年

Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

生物模擬市場成長與趨勢

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球生物模擬市場規模預計將達到 100 億美元。預計2025年至2030年該市場將以17.0%的複合年成長率擴張。市場成長的主要促進因素包括慢性病盛行率的增加、醫療保健數位化的增加以及生物模擬解決方案在臨床測試和研究中的使用。

隨著急診疾病的流行，對藥物發現和開發的需求不斷成長，以及研發活動資金的增加，正在推動生物模擬解決方案的採用。此外，高藥物損耗率導致臨床測試成本增加，因此臨床上必須採用In Silico生物方法。這種方法透過預測生物交互作用顯著降低了藥物失敗的可能性，並降低了整體成本。

藥物復發率的上升、抗藥性病例的增加以及治療愛滋病等疾病的藥物的供應有限，正在推動生物模擬在藥物開發和藥物發現等應用中的採用，這是臨床上的當務之急。

COVID-19 大流行也對市場成長產生了重大影響。例如，Simulations Plus 於 2020 年 3 月推出了 StrategiesPlus COVID-19 ACT 計劃，以快速為參與 COVID-19 研究的任何組織提供諮詢支援。公司聲明，截至2020年11月，其業務未受到重大不利影響。然而，COVID-19 的持續蔓延以及受影響國家政府採取的行動可能會擾亂供應鏈，並對公司的業務和財務表現產生不利影響。

模擬軟體和服務的需求快速成長也歸因於其高成本效益。生物模擬解決方案能夠在產品開發的早期階段經濟高效地預測臨床實驗藥物的毒性、副作用和功效，從而降低後期藥物復發和不利事件的可能性。

市場參與企業正在投資一系列策略舉措，包括收購、合併、聯盟和產品發布，以保持市場競爭力。例如，2022 年 1 月，Simulations Plus Inc. 與一家動物保健公司合作，檢驗目前的動物生理藥物動力學 (PBPK) 模型。透過此次融資合作，該公司旨在為 GastroPlus 平台添加重要的新物種。此外，2021年11月，橫河電機收購了Insilico BIoTechnology AG，這是一家開發和提供生物程序軟體和服務的德國公司。

生物模擬市場報告亮點

  • 軟體佔據市場主導地位，2024 年銷售佔有率將達到 62.02%。這是由於可以滿足特定研發要求的特定應用軟體的可用性。
  • 2024年，藥物發現和開發細分市場佔據最大市場佔有率，為55.43%，這歸因於藥物開發流程的增加。
  • 2024 年，腫瘤學佔收益佔有率。在腫瘤學中，生物模擬對於了解腫瘤動態、治療反應和影響癌症結果的患者特定因素至關重要。
  • 雲端基礎的部署模式佔據市場主導地位，2024 年收益佔有率最大，超過 43.00%。
  • 2024 年，基於授權的模式佔收益佔有率。該模型的優點在於，它使用戶能夠存取複雜的工具，而無需對基礎設施或開發進行大量投資。
  • 2024年，生命科學公司佔收益佔有率最大。這些公司擴大採用模擬軟體作為藥物開發和研發的重要工具。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章生物模擬市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 生物模擬市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • COVID-19 影響分析

第 4 章 生物模擬市場：依產品估算與趨勢分析

  • 細分儀表板
  • 全球生物模擬市場產品波動分析
  • 2018-2030年全球生物模擬市場規模及趨勢分析（依產品）
  • 軟體
    • 分子建模與模擬軟體
    • 臨床試驗設計軟體
    • PK/PD建模與模擬軟體
    • Pbpk 建模與模擬軟體
    • 毒性預測軟體
    • 其他軟體
  • 服務
    • 合約服務
    • 諮詢
    • 其他（實施、培訓、支援等）

第5章生物模擬市場：按應用估計和趨勢分析

  • 細分儀表板
  • 全球生物模擬市場應用波動分析
  • 2018-2030 年全球生物模擬市場規模與趨勢分析（按應用）
  • 藥物發現與開發
  • 疾病模型
  • 其他（精準醫學、毒理學等）

第6章生物模擬市場：治療領域的估計與趨勢分析

  • 細分儀表板
  • 全球生物模擬市場治療領域波動分析
  • 2018-2030年全球生物模擬市場規模與趨勢分析（依治療領域）
  • 腫瘤學
  • 心血管疾病
  • 感染疾病
  • 神經系統疾病
  • 其他

第7章 生物模擬市場：依發展模型估算及趨勢分析

  • 細分儀表板
  • 全球生物模擬市場發展模式波動分析
  • 2018-2030 年全球生物模擬市場規模與趨勢分析（依部署模式）
  • 雲端基礎
  • 本地
  • 混合模式

第8章 生物模擬市場：定價模式估算與趨勢分析

  • 細分儀表板
  • 全球生物模擬市場定價模式波動分析
  • 2018-2030年全球生物模擬市場規模及趨勢分析（以定價模式）
  • 基於許可的模型
  • 訂閱模式
  • 基於服務的模型
  • 計量收費模式

第9章生物模擬市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 全球生物模擬市場的最終用途變化分析
  • 2018-2030 年全球生物模擬市場規模與趨勢分析（依最終用途）
  • 生命科學公司
    • 製藥公司
    • 生物製藥公司
    • 醫療設備公司
    • CRO/CDMO
  • 學術研究所
  • 其他（監管機構等）

第10章生物模擬市場：按地區估算及趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章競爭格局

  • 公司/競爭對手分類
  • 策略規劃
  • 公司市場地位/佔有率分析，2024 年
  • 公司簡介/上市公司
    • Certara, USA
    • Dassault Systemes
    • Advanced Chemistry Development
    • Simulation Plus
    • Schrodinger, Inc.
    • Chemical Computing Group ULC
    • Physiomics Plc
    • Rosa &Co. LLC
    • BioSimulation Consulting Inc.
    • Genedata AG
    • Instem Group of Companies
    • PPD, Inc.
    • Yokogawa Insilico BIoTechnology GmbH
Product Code: GVR-1-68038-051-4

Biosimulation Market Growth & Trends:

The global biosimulation market size is expected to reach USD 10.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 17.0% from 2025 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights:

  • Software dominated the market, with a revenue share of 62.02% in 2024. This can be attributed to the availability of application-specific software catering to specific research and development requirements.
  • The drug development segment held the largest market share of 55.43% in 2024, driven by the increasing number of drug development processes.
  • Oncology held the largest revenue share in 2024. In oncology, biosimulation is crucial in understanding tumor dynamics, treatment responses, and patient-specific factors influencing cancer outcomes.
  • Cloud-based deployment model dominated the market and held the largest revenue share of over 43.00% in 2024 and is expected to grow at the fastest CAGR during the forecast period.
  • License-based model held the largest revenue share in 2024. The advantage of this model is that it provides users with access to sophisticated tools without the need for substantial investments in infrastructure or development.
  • Life science companies accounted for the largest revenue share in 2024. These companies are increasingly adopting biosimulation software as a critical tool in drug development and research.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. Therapeutic Area Segment
    • 1.2.4. Deployment Model Segment
    • 1.2.5. Pricing Model Segment
    • 1.2.6. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Biosimulation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Growing demand for personalized medicine
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with biosimulation technology and software
      • 3.2.2.2. Stringent regulatory requirements
  • 3.3. Biosimulation Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
      • 3.3.2.6. Social Landscape
  • 3.4. COVID-19 Impact Analysis

Chapter 4. Biosimulation Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biosimulation Market Product Movement Analysis
  • 4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
  • 4.4. Software
    • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2. Molecular Modeling & Simulation Software
      • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.3. Clinical Trial Design Software
      • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.4. PK/PD Modeling and Simulation Software
      • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.5. Pbpk Modeling and Simulation Software
      • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.6. Toxicity Prediction Software
      • 4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.7. Other Software
      • 4.4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2. Contract Services
      • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.3. Consulting
      • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.4. Other (Implementation, Training, & Support, etc.)
      • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Biosimulation Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biosimulation Market Application Movement Analysis
  • 5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
  • 5.4. Drug Discovery & Development
    • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Disease Modeling
    • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Other (Precision Medicine, Toxicology, etc.)
    • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
  • 6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Infectious Disease
    • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Neurological Disorders
    • 6.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Biosimulation Market: Deployment Model Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Biosimulation Market Deployment Model Movement Analysis
  • 7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2018 - 2030 (USD Million)
  • 7.4. Cloud-based
    • 7.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. On-premises
    • 7.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Hybrid Model
    • 7.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Biosimulation Market: Pricing Model Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Biosimulation Market Pricing Model Movement Analysis
  • 8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2018 - 2030 (USD Million)
  • 8.4. License-based Model
    • 8.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5. Subscription-based Model
    • 8.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.6. Service-based Model
    • 8.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.7. Pay Per Use Model
    • 8.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Biosimulation Market: End Use Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Biosimulation Market End Use Movement Analysis
  • 9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
  • 9.4. Life Science Companies
    • 9.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.2. Pharmaceutical Companies
      • 9.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.3. Biopharma Companies
      • 9.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.4. Medical Device Companies
      • 9.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.5. CROs/CDMOs
      • 9.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5. Academic Research Institutions
    • 9.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6. Others (Regulatory Authorities, etc.)
    • 9.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Biosimulation Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
  • 10.4. North America
    • 10.4.1. U.S.
      • 10.4.1.1. Key country dynamics
      • 10.4.1.2. Regulatory framework
      • 10.4.1.3. Competitive scenario
      • 10.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.4.2. Canada
      • 10.4.2.1. Key country dynamics
      • 10.4.2.2. Regulatory framework
      • 10.4.2.3. Competitive scenario
      • 10.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.4.3. Mexico
      • 10.4.3.1. Key country dynamics
      • 10.4.3.2. Regulatory framework
      • 10.4.3.3. Competitive scenario
      • 10.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. UK
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.2. Germany
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.3. France
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.4. Italy
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.5. Spain
      • 10.5.5.1. Key country dynamics
      • 10.5.5.2. Regulatory framework
      • 10.5.5.3. Competitive scenario
      • 10.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.6. Norway
      • 10.5.6.1. Key country dynamics
      • 10.5.6.2. Regulatory framework
      • 10.5.6.3. Competitive scenario
      • 10.5.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.7. Sweden
      • 10.5.7.1. Key country dynamics
      • 10.5.7.2. Regulatory framework
      • 10.5.7.3. Competitive scenario
      • 10.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.5.8. Denmark
      • 10.5.8.1. Key country dynamics
      • 10.5.8.2. Regulatory framework
      • 10.5.8.3. Competitive scenario
      • 10.5.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Japan
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.6.3. India
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.6.4. Australia
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.6.5. South Korea
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.6.6. Thailand
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Brazil
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.7.2. Argentina
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. South Africa
      • 10.8.1.1. Key country dynamics
      • 10.8.1.2. Regulatory framework
      • 10.8.1.3. Competitive scenario
      • 10.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.8.2. Saudi Arabia
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.8.3. UAE
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 10.8.4. Kuwait
      • 10.8.4.1. Key country dynamics
      • 10.8.4.2. Regulatory framework
      • 10.8.4.3. Competitive scenario
      • 10.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company/Competition Categorization
  • 11.2. Strategy Mapping
  • 11.3. Company Market Position/Share Analysis, 2024
  • 11.4. Company Profiles/Listing
    • 11.4.1. Certara, USA
      • 11.4.1.1. Company overview
      • 11.4.1.2. Financial performance
      • 11.4.1.3. Product benchmarking
      • 11.4.1.4. Strategic initiatives
    • 11.4.2. Dassault Systemes
      • 11.4.2.1. Company overview
      • 11.4.2.2. Financial performance
      • 11.4.2.3. Product benchmarking
      • 11.4.2.4. Strategic initiatives
    • 11.4.3. Advanced Chemistry Development
      • 11.4.3.1. Company overview
      • 11.4.3.2. Financial performance
      • 11.4.3.3. Product benchmarking
      • 11.4.3.4. Strategic initiatives
    • 11.4.4. Simulation Plus
      • 11.4.4.1. Company overview
      • 11.4.4.2. Financial performance
      • 11.4.4.3. Product benchmarking
      • 11.4.4.4. Strategic initiatives
    • 11.4.5. Schrodinger, Inc.
      • 11.4.5.1. Company overview
      • 11.4.5.2. Financial performance
      • 11.4.5.3. Product benchmarking
      • 11.4.5.4. Strategic initiatives
    • 11.4.6. Chemical Computing Group ULC
      • 11.4.6.1. Company overview
      • 11.4.6.2. Financial performance
      • 11.4.6.3. Product benchmarking
      • 11.4.6.4. Strategic initiatives
    • 11.4.7. Physiomics Plc
      • 11.4.7.1. Company overview
      • 11.4.7.2. Financial performance
      • 11.4.7.3. Product benchmarking
      • 11.4.7.4. Strategic initiatives
    • 11.4.8. Rosa & Co. LLC
      • 11.4.8.1. Company overview
      • 11.4.8.2. Financial performance
      • 11.4.8.3. Product benchmarking
      • 11.4.8.4. Strategic initiatives
    • 11.4.9. BioSimulation Consulting Inc.
      • 11.4.9.1. Company overview
      • 11.4.9.2. Financial performance
      • 11.4.9.3. Product benchmarking
      • 11.4.9.4. Strategic initiatives
    • 11.4.10. Genedata AG
      • 11.4.10.1. Company overview
      • 11.4.10.2. Financial performance
      • 11.4.10.3. Product benchmarking
      • 11.4.10.4. Strategic initiatives
    • 11.4.11. Instem Group of Companies
      • 11.4.11.1. Company overview
      • 11.4.11.2. Financial performance
      • 11.4.11.3. Product benchmarking
      • 11.4.11.4. Strategic initiatives
    • 11.4.12. PPD, Inc.
      • 11.4.12.1. Company overview
      • 11.4.12.2. Financial performance
      • 11.4.12.3. Product benchmarking
      • 11.4.12.4. Strategic initiatives
    • 11.4.13. Yokogawa Insilico Biotechnology GmbH
      • 11.4.13.1. Company overview
      • 11.4.13.2. Financial performance
      • 11.4.13.3. Product benchmarking
      • 11.4.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global biosimulation market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 6 Global biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 7 Global biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 8 Global biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 9 North America biosimulation market, by country, 2018 - 2030 (USD Million)
  • Table 10 North America biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 11 North America biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 12 North America biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 13 North America biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 14 North America biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 15 North America biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 16 U.S. biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 17 U.S. biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 18 U.S. biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 19 U.S. biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 20 U.S. biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 21 U.S. biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Canada biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 23 Canada biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 24 Canada biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 25 Canada biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 26 Canada biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 27 Canada biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Mexico biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 29 Mexico biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 30 Mexico biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 31 Mexico biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 32 Mexico biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 33 Mexico biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Europe biosimulation market, by country, 2018 - 2030 (USD Million)
  • Table 35 Europe biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 36 Europe biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 37 Europe biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 38 Europe biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 39 Europe biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 40 Europe biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 41 UK biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 42 UK biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 43 UK biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 44 UK biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 45 UK biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 46 UK biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Germany biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 48 Germany biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 49 Germany biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 50 Germany biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 51 Germany biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 52 Germany biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 53 France biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 54 France biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 55 France biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 56 France biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 57 France biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 58 France biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Italy biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 60 Italy biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 61 Italy biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 62 Italy biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 63 Italy biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 64 Italy biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Spain biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 66 Spain biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 67 Spain biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 68 Spain biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 69 Spain biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 70 Spain biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 71 Denmark biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 72 Denmark biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 73 Denmark biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 74 Denmark biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 75 Denmark biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 76 Denmark biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Sweden biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 78 Sweden biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 79 Sweden biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 80 Sweden biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 81 Sweden biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 82 Sweden biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 83 Norway biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 84 Norway biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 85 Norway biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 86 Norway biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 87 Norway biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 88 Norway biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Asia Pacific biosimulation market, by country, 2018 - 2030 (USD Million)
  • Table 90 Asia Pacific biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 91 Asia Pacific biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 92 Asia Pacific biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 93 Asia Pacific biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 94 Asia Pacific biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 95 Asia Pacific biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 96 China biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 97 China biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 98 China biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 99 China biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 100 China biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 101 China biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 102 Japan biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 103 Japan biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 104 Japan biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 105 Japan biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 106 Japan biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 107 Japan biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 108 India biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 109 India biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 110 India biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 111 India biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 112 South Korea biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 113 India biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 114 South Korea biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 115 South Korea biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 116 South Korea biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 117 South Korea biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 118 South Korea biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 119 South Korea biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 120 Australia biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 121 Australia biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 122 Australia biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 123 Australia biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 124 Australia biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 125 Australia biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 126 Thailand biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 127 Thailand biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 128 Thailand biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 129 Thailand biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 130 Thailand biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 131 Thailand biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 132 Latin America biosimulation market, by country, 2018 - 2030 (USD Million)
  • Table 133 Latin America biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 134 Latin America biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 135 Latin America biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 136 Latin America biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 137 Latin America biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 138 Latin America biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 139 Brazil biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 140 Brazil biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 141 Brazil biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 142 Brazil biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 143 Brazil biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 144 Brazil biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 145 Argentina biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 146 Argentina biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 147 Argentina biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 148 Argentina biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 149 Argentina biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 150 Argentina biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 151 MEA biosimulation market, by country, 2018 - 2030 (USD Million)
  • Table 152 MEA biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 153 MEA biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 154 MEA biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 155 MEA biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 156 MEA biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 157 MEA biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 158 South Africa biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 159 South Africa biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 160 South Africa biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 161 South Africa biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 162 South Africa biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 163 South Africa biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 164 Saudi Arabia biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 165 Saudi Arabia biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 166 Saudi Arabia biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 167 Saudi Arabia biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 168 Saudi Arabia biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 169 Saudi Arabia biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 170 UAE biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 171 UAE biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 172 UAE biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 173 UAE biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 174 UAE biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 175 UAE biosimulation market, by end use, 2018 - 2030 (USD Million)
  • Table 176 Kuwait biosimulation market, by product, 2018 - 2030 (USD Million)
  • Table 177 Kuwait biosimulation market, by application, 2018 - 2030 (USD Million)
  • Table 178 Kuwait biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 179 Kuwait biosimulation market, by deployment model, 2018 - 2030 (USD Million)
  • Table 180 Kuwait biosimulation market, by pricing model, 2018 - 2030 (USD Million)
  • Table 181 Kuwait biosimulation market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Biosimulation market: Market outlook
  • Fig. 5 Biosimulation market: Segment outlook
  • Fig. 6 Biosimulation market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Biosimulation market driver impact
  • Fig. 9 Biosimulation market restraint impact
  • Fig. 10 Biosimulation market: Product outlook and key takeaways
  • Fig. 11 Biosimulation market: Product movement analysis
  • Fig. 12 Software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Molecular modeling & simulation software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Clinical trial design software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 PK/PD modeling and simulation software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Pbpk modeling and simulation software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Toxicity prediction software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other software market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Contract services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Consulting services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Other services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Biosimulation market: Application outlook and key takeaways
  • Fig. 24 Biosimulation market: Application movement analysis
  • Fig. 25 Drug discovery & development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Disease modeling market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Biosimulation market: Therapeutic area outlook and key takeaways
  • Fig. 29 Biosimulation market: Therapeutic area movement analysis
  • Fig. 30 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Cardiovascular disease modeling market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Infectious disease modeling market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Neurological disorders modeling market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Biosimulation market: Deployment model outlook and key takeaways
  • Fig. 36 Biosimulation market: Deployment model movement analysis
  • Fig. 37 Cloud-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 On-premises market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Hybrid market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Biosimulation market: Pricing model outlook and key takeaways
  • Fig. 41 Biosimulation market: Pricing model movement analysis
  • Fig. 42 License-based model market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Subscription-based model market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Service-based model market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Pay-per-use model market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Biosimulation market: End use outlook and key takeaways
  • Fig. 47 Biosimulation market: End use movement analysis
  • Fig. 48 Life Science companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Pharmaceutical companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 50 Biopharma companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 51 Medical device companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 52 CROs/CDMOs market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 53 Academic institutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 55 Global biosimulation market: Regional outlook and key takeaways
  • Fig. 56 Global biosimulation market: Regional movement analysis
  • Fig. 57 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)